IRIS
ROSSETTI, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.653
NA - Nord America 2.868
AS - Asia 652
SA - Sud America 56
AF - Africa 36
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 7.278
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.843
GB - Regno Unito 895
IT - Italia 879
IE - Irlanda 607
SE - Svezia 294
CN - Cina 279
RU - Federazione Russa 215
FR - Francia 197
DE - Germania 179
UA - Ucraina 143
SG - Singapore 139
FI - Finlandia 89
VN - Vietnam 60
ES - Italia 49
IR - Iran 38
BR - Brasile 37
IN - India 35
NL - Olanda 30
TR - Turchia 21
CA - Canada 19
HK - Hong Kong 19
CI - Costa d'Avorio 15
PL - Polonia 15
BE - Belgio 12
CZ - Repubblica Ceca 12
CO - Colombia 10
AU - Australia 8
PK - Pakistan 8
DK - Danimarca 7
ZA - Sudafrica 7
IL - Israele 6
MX - Messico 6
PH - Filippine 6
CH - Svizzera 5
EU - Europa 4
KR - Corea 4
LV - Lettonia 4
MN - Mongolia 4
SK - Slovacchia (Repubblica Slovacca) 4
BD - Bangladesh 3
EC - Ecuador 3
ID - Indonesia 3
LK - Sri Lanka 3
LT - Lituania 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
AZ - Azerbaigian 2
BW - Botswana 2
CL - Cile 2
CY - Cipro 2
DZ - Algeria 2
EG - Egitto 2
IM - Isola di Man 2
JP - Giappone 2
KG - Kirghizistan 2
LU - Lussemburgo 2
NG - Nigeria 2
NO - Norvegia 2
PT - Portogallo 2
QA - Qatar 2
RO - Romania 2
SN - Senegal 2
TH - Thailandia 2
UY - Uruguay 2
UZ - Uzbekistan 2
BN - Brunei Darussalam 1
BY - Bielorussia 1
ET - Etiopia 1
GH - Ghana 1
HR - Croazia 1
IQ - Iraq 1
KH - Cambogia 1
KW - Kuwait 1
MA - Marocco 1
MY - Malesia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
PS - Palestinian Territory 1
PY - Paraguay 1
SA - Arabia Saudita 1
UG - Uganda 1
Totale 7.278
Salva come PNG Salva come JPEG
Città #
Southend 781
Dublin 591
Chandler 335
Fairfield 316
Santa Clara 231
Ashburn 216
Siena 175
Menlo Park 146
Woodbridge 123
Seattle 117
Jacksonville 114
Ann Arbor 109
Cambridge 108
Wilmington 103
Singapore 97
Houston 95
Princeton 91
Beijing 83
Helsinki 63
New York 57
Florence 56
Dong Ket 55
Nanjing 46
Rome 45
Milan 43
Munich 43
Málaga 38
Boardman 28
Dearborn 24
Shanghai 24
San Diego 23
San Mateo 23
Moscow 19
Fremont 17
Los Angeles 17
Nottingham 16
Abidjan 15
London 15
Catania 13
Izmir 13
Karaj 13
Brussels 12
Chicago 12
Tehran 11
Comun Nuovo 10
Dallas 10
Horsham 10
Nuremberg 10
Perugia 10
Toronto 10
Coventry 9
Frankfurt am Main 9
Kowloon 9
Lancaster 9
Nanchang 9
Shenyang 9
Washington 9
Brno 8
Jiaxing 8
Paris 8
Tianjin 8
Guangzhou 7
Hebei 7
Jinan 7
Norwalk 7
Redwood City 7
San Francisco 7
Zhengzhou 7
Aachen 6
Amsterdam 6
Anagni 6
Central 6
Falls Church 6
Laguna Beach 6
Lappeenranta 6
Phoenix 6
Pisa 6
Bologna 5
Brescia 5
Catanzaro 5
Chia 5
Espoo 5
Naples 5
Ningbo 5
Somerset West 5
Stanford 5
Taizhou 5
Barolo 4
Carrara 4
Corby 4
Delhi 4
Fiesole 4
Gorizia 4
Grosseto 4
Hangzhou 4
Ho Chi Minh City 4
Hyderabad 4
Lanzhou 4
Melbourne 4
Multan 4
Totale 4.932
Salva come PNG Salva come JPEG
Nome #
Staphylococcus aureus vaccine preclinical and clinical development: current state of the art 409
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 266
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 223
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 205
Genetic mechanisms of critical illness in COVID-19 205
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 202
Antirheumatic agents in covid-19: is IL-6 the right target? 202
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 191
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 190
HCMV infection in renal transplant recipients: a retrospective cohort study 187
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 185
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 182
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 176
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 175
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients 174
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 174
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 169
Un caso di “insolita” spondilodiscite da Staphylococcus capitis 168
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 163
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 158
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 153
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 149
FALLIMENTO VIROLOGICO PRECOCE CON SELEZIONE RAPIDA DI FARMACORESISTENZA IN UN PAZIENTE CON HCV GENOTIPO 1, TRATTATO CON PEGINTERFERON, RIBAVIRINA E TELAPREVIR 146
MIASI CAVITARIA A LOCALIZZAZIONE NASALE DA OESTRUS OVIS: UN CASO CLINICO 145
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 145
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 140
Mapping the human genetic architecture of COVID-19 136
Serial KL-6 measurements in COVID-19 patients 129
Use of Miltefosine in a Patient With Mucosal Leishmaniasis and HIV-coinfection: A Challenge in Long-Term Management 124
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 120
Il ruolo dell'infezione da CMV e del suo monitoraggio attivo nella nuova era dei trapianti di rene: risultati di una coorte completa 113
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 111
An explainable model of host genetic interactions linked to COVID-19 severity 108
Which screening for Leishmania infantum in asymptomatic blood donors? 106
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 105
Gestione clinica di effetti collaterali multipli in un paziente con epatite cronica da HCV in trattamento con terapia triplice comprendente telaprevir 100
Laboratory diagnosis of Mycoplasma pneumoniae infections: data analysis from clinical practice 98
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV 95
Infezione da Mycobacterium marinum: le difficoltà diagnostiche e terapeutiche di un caso raro 95
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 93
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: A multi-cohort study 89
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 87
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 86
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 82
Discordant liver fibrosis predictors in virologically suppressed people living with hiv without hepatitis virus infection 78
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe 73
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: Results from a European multi-cohort study 69
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 67
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 59
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 56
Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019 55
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 52
Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen 51
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 39
Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study 38
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients 36
The Uprise of Human Leishmaniasis in Tuscany, Central Italy: Clinical and Epidemiological Data from a Multicenter Study 17
Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network) 16
null 14
Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID‐19 pandemic 9
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort 8
Totale 7.496
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.017
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.017
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020461 0 0 0 0 0 71 76 91 57 86 34 46
2020/20211.022 36 59 43 68 110 79 77 120 126 99 92 113
2021/20221.008 94 94 48 99 48 37 54 52 77 91 103 211
2022/20231.322 63 142 166 134 99 217 76 127 124 74 61 39
2023/20241.284 43 48 115 77 72 302 354 60 11 52 56 94
2024/20251.061 98 98 288 150 286 141 0 0 0 0 0 0
Totale 7.496